Stem cell therapy in patients with multiple sclerosis
It is an unusual week that does not see some new headline in the lay press concerning stem cells and their exciting potential for curing this or that disease. Predictably, conditions that are currently considered incurable claim the most attention, and amongst these multiple sclerosis (MS) is hardly the least conspicuous. The challenging emergence of any number of profiteering outfits dedicated to pocketing enormous sums from the sale directly to patients of so-called stem cell therapies has added controversy to the already much excited lay media. Claims and counterclaims rebound, leaving not only patients and carers but also the clinical and scientific community bemused if not a little weary.
Media headlines apart, there is of course nothing unusual or inappropriate about clinical uncertainty regarding the efficacy or promise of an emerging therapy. But in relation to MS, the (not quite) simultaneous appearance of two very different species of stem cell therapy has complicated matters. Two significant position papers in this issue of Multiple Sclerosis offer valuable insights into the current status of one form of stem cell therapy Á which might be termed immune reconstruction by haematopoetic or bone marrow stem cell transplantation.
The second type, tissue reconstruction by stem cell transplantation, aiming to exploit the transdifferentiation and reparative properties of stem cells (including, to complicate matters further, bone marrow-derived or mesenchymal stem cells), remains as yet an experimental technique in relation to MS, albeit on the verge of clinical study and Á away from neurology Á at a much more advanced stage of clinical testing in cardiac disease [1] .
A topic already more than sufficiently complex for most of us has, however, received in the past couple of years an added layer of intrigue. It is increasingly apparent that the clear mechanistic boundary, apparently logically assembled, between tissue reconstructive stem cell therapy and immune reconstructive (bone marrow) stem cell therapy is not so much of a boundary after all. Increasingly it is accepted that when stem cells contribute to repair they utilize a variety of mechanisms. Direct transdifferentiation to replace damaged specialized cells, whilst it may occur, seems often not to be quantitatively very significant, and may represent only a very minor contribution to the repair process Á which is both surprising and ironic, as it was the pluripotent ability of stem cells that triggered such an explosion of interest and excitement (and funding!) in their reparative potential, and more generally in regenerative medicine. In fact, a variety of other mechanisms, including the encouragement of angiogenesis, neuroprotection, growth factor production, the recruitment and stimulation of endogenous (tissue-based) progenitors, and modulation of the local immune response may, in different situations, diseases and tissues, play much more important roles than mere transdifferentiation [2, 3] . And of course the last of these, the significant ability of (perhaps particularly) mesenchymal stem cells to modulate immune responses [4] , shows clearly that so-called tissuereconstructive and so-called immune-reconstructive stem cell therapies have too rapidly been nosologically divided.
So, returning to clinical practice, what have we learned about therapy from the two papers in this issue? Harry Openshaw and colleagues [pp 824 Á 825] summarize the discussions relating to MS held during a conference (Cellular Therapy for Treatment of Autoimmune Diseases) held in October last year in California. On pages 814 Á 823, Riccardo Saccardi (a co-author also of the above 'Meetings' paper) and colleagues, on behalf of the European Blood and Marrow Transplantation Group (EBMT), provide an update on the mixed group of 178 patients on their registry who have received treatment with autologous haematopoietic stem cells and 14 who had bone marrow transplantation, all following immune-ablating induction therapy (of slightly varying protocols).
One striking aspect of the European data is the severity of disability of patients treated Á a median Expanded Disability Status Scale (EDSS) score of 6.5. Given the increasing appreciation of the role of neurodegeneration in the progression of disability in MS, the suggestion that immune and inflammatory mechanisms are far less important in this process than in relapsing MS, and the proposition that neuroprotection may therefore be a more appropriate treatment strategy for progression than immune-based therapies, this might be considered surprising. In fact, benefit from haematopoetic stem cell transplantation is reported in these patients. EDSS at follow-up (median 41.7 months) had decreased or remained stable in 63% of cases.
Does this suggest we would be wrong to jettison immune approaches to treating patients with established progression in MS? The results certainly differ from data from alternative forms of immune therapy Á for example, Campath-1H therapy where very intense lymphocyte depletion has little effect on progressive disability if given after progression has clearly commenced [5] . In the EBMT study, neurological follow-up was only available on 142 of the 178 patients, which might potentially skew the results, and no data are offered as to whether recent relapse (or steroid use) precluded entry, the authors commendably acknowledging quite openly the 'lacking of information on the presence of relapses before and after therapy'. As given, the ASTIMS inclusion criteria include reference to decline in EDSS over the past year without appearing to stipulate an absence of recent relapse activity to account for this decline. Could stabilization or spontaneous improvement following relapse therefore contribute to the overall EDSS results? Interpretation is perhaps also complicated by the fact that 124 patients had also received (as part of their MS therapy, not just their conditioning) various immune suppressant or immune-modulating therapies, including azathioprine, interferons or cyclophosphamide.
Notwithstanding these points, which as the authors point out, may help justify further study, we should recall that histopathologically even primary progressive MS exhibits significant inflammation. While this may be quantitatively less than that seen in relapsing Á remitting disease, a role for the immune system Á and antibodies in particular Á continues to be supported [6] . A second, unrelated aspect of increasing disability is that relapse activity makes a minor but nonetheless significant contribution to residual and accumulating functional deficits in progressive MS [7] . Therefore, as the results reported here imply, we should indeed perhaps pause before neglecting inflammation and entirely abandoning anti-inflammatory treatments in our rush to embrace neurodegeneration as the sole cause of disability progression. None of which is to overlook what seems a far more unambiguous result, the very dramatic reduction in relapse rate in the results emerging both in Europe and from the Americas.
Toxicity remains a serious consideration. Early, 'non-neurological' toxicity was reported in 56% of evaluable patients (a level expected of autologous HSCT in any setting) and neurological toxicity in 17% of patients. Later toxicity (after two months) was seen in 6% of patients, mostly infective (such as Herpes zoster infection) or immunological (such as new autoimmune thyroid disease: both intriguingly similar to that seen after Campath-1H treatment). Nine patients died for reasons considered related to transplant procedure, though a further five patients died from progression of their MS and were not considered to be transplant-related deaths. None of the former deaths occurred since 2001; the authors indicating that avoiding high-intensity regimens and better patient selection substantially reduce this risk. One death is reported among eleven patients treated in the Canadian trial. So, do we yet know the place of autologous haematopoetic stem cell transplantation in the treatment of severe and aggressive MS? The answer must remain 'not yet', despite the valuable new information in these useful papers. As Riccardo Saccardi says, there 'needs to be . . . prospective, randomized controlled trials'. Given the rapid emergence of other new therapies, particularly monoclonal antibodies such as Campath-1H, natalizumab and others, it may well be that such trials need to be controlled by comparison with one or other of these newer and apparently more potent agents.
